{"slug":"ipamorelin","verification":{"valid":true,"entries":2,"head":"f183fd3e646c0bfea685be8119552acbad6dbe7579682bbb8b87a65c716cb6fe"},"count":2,"models":["grok-4.3"],"yield":{"passes":2,"energy_spent_rows":0,"total_cost_usd":0,"waste_cost_usd":0,"total_tokens":0,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok-4.3","passes":2,"cost_usd":0,"tokens_total":0,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T17:03:05.663Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"ipamorelin","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"dd5782286f36c3171597d33c64205edc1c93f890d52829827b54fdfce4f6cecc"},{"seq":1,"id":"k2","ts":"2026-06-29T17:03:24.690Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39043357/","title":"The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism","quote":"This study investigated whether ghrelin mimetics, namely anamorelin and ipamorelin, can alleviate weight loss and inhibition of feeding observed during acute and delayed phases of cisplatin-induced emesis in ferrets. ... Neither of compounds administered i.p. had any effect on cisplatin-induced acute or delayed emesis, but both inhibited associated cisplatin-induced weight loss on the last day of delayed phase (48-72 h) by approximately 24 %.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/41966639/","title":"Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance","quote":"Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 ... ipamorelin, MOTS-C ... Many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"dd5782286f36c3171597d33c64205edc1c93f890d52829827b54fdfce4f6cecc","hash":"f183fd3e646c0bfea685be8119552acbad6dbe7579682bbb8b87a65c716cb6fe"}]}